Erdafitinib and Troleandomycin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Troleandomycin
No brand names on recordErdafitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased erdafitinib exposure
Interaction Deep Dive
Coadministration of erdafitinib (a CYP3A4 substrate) with a strong CYP3A4 inhibitor may lead to increased erdafitinib exposure, increasing the risk for erdafitinib-related toxicity. Consider alternative therapies that are not strong CYP3A4 inhibitors during treatment with erdafitinib. If concomitant use is unavoidable, closely monitor for adverse events and consider dose modifications accordingly. If the strong CYP3A4 inhibitor is discontinued, the erdafitinib dose may be increased in the absence of drug-related toxicity1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of erdafitinib
Literature reports
1 report — tap to read
a) Erdafitinib mean ratios for Cmax and AUC(inf) were increased 105% and 134%, respectively, when coadministered with itraconazole (a strong CYP3A4 inhibitor and P-gp inhibitor) compared with erdafitinib alone 1.
Common questions
Can I take Erdafitinib and Troleandomycin together?
Increased erdafitinib exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Erdafitinib and Troleandomycin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Erdafitinib or Troleandomycin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: BALVERSA(R) oral tablets, erdafitinib oral tablets. Janssen Products LP (per FDA), Horsham, PA, 2024. DailyMed
Keep reading about Troleandomycin
Keep reading about Erdafitinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist